Medscape4d
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...
The New England Journal of Medicine7d
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to CF33-hNIS in Cholangiocarcinoma
CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...
Business Insider5d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
E+P continues to have a comparable safety profile to pembrolizumab alone other than injection site reactions as expected with ...
MedPage Today4d
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...
The American Journal of Managed Care7d
Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
In terms of combining IO102-IO103 with immune checkpoint inhibition, such as the PD-1 antibody pembrolizumab in our phase 2 trial that I presented at ESMO, the rationale is that subcutaneous injection ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase I trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Hosted on MSN14d
Novartis teams up with Lindy Biosciences to improve biologic delivery
This enhances drug stability, reduces injection volumes, and enables more convenient ... developing a SC formulation of its blockbuster checkpoint inhibitor Keytruda (pembrolizumab). In addition to ...
GlobalData on MSN8d
ESMO 2024: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...
The New England Journal of Medicine6d
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...